Key result
Sepsis-associated cardiogenic shock under Impella is linked to ~4.7-fold higher in-hospital mortality.
Why the study?
Refractory cardiogenic shock carries high mortality despite advances in care, and although percutaneous left ventricular support using Impella is widely used, real-world outcomes may differ substantially by underlying shock etiology and phenotype.
Does percutaneous left ventricular support using Impella 2.5/CP result in different in-hospital and 12-month mortality outcomes across distinct cardiogenic shock phenotypes in adults with refractory cardiogenic shock?
Cohort (n=409)
No
Does percutaneous left ventricular support using Impella 2.5/CP result in different in-hospital and 12-month mortality outcomes across distinct cardiogenic shock phenotypes in adults with refractory cardiogenic shock?
In patients with refractory cardiogenic shock treated with Impella 2.5/CP, short- and long-term survival is strongly phenotype-dependent, with sepsis-associated cardiogenic shock carrying an extremely high in-hospital mortality of 80.6%.
Answers are grounded in this paper and cite their sources.
Sepsis phenotype signals markedly higher Impella-supported mortality risk; hypothesis-generating for etiology-specific trials before practice change.
Background Refractory cardiogenic shock (CS) remains associated with unacceptably high mortality despite advances in intensive-care and coronary intervention strategies. Percutaneous left ventricular support using Impella is widely used, yet real-world outcomes may differ substantially by underlying shock etiology and phenotype. Methods We performed a retrospective single-center cohort study of adults treated with Impella 2.5/CP for refractory CS over a 9-year period. Patients were classified as acute coronary syndrome (ACS), dilated cardiomyopathy (DCM)/myocarditis, severe aortic stenosis (AS), sepsis-associated CS, or other causes. Endpoints were all-cause in-hospital and 12-month mortality. Multivariable logistic regression adjusted for age, sex, lactate, vasoactive score, Impella type was conducted; a sensitivity model additionally included creatinine. Results Among 409 patients (mean age 69.99 ± 11.56 years; 75.6% male), ACS was the leading phenotype ( n = 269), followed by DCM/myocarditis ( n = 53), AS ( n = 32), sepsis-associated CS ( n = 36), and other causes ( n = 19). Impella CP was used in 227 patients (55.5%). Overall in-hospital mortality was 48.9% and differed across phenotypes, being highest in sepsis-associated CS (80.6%; chi-squared p < 0.001). Sepsis remained independently associated with in-hospital death after adjustment (adjusted odds ratio 4.65, 95% CI 2.03–12.07, p = 0.0006) for major confounders; finding was consistent after additional adjustment for creatinine (adjusted odds ratio 4.17, 95% CI 1.63–12.26, p = 0.0023). Major bleeding occurred in 14.9%, limb ischemia in 11.7%, pseudoaneurysm in 4.9%, and stroke in 1.0% of the patients. Twelve-month survival analysis also demonstrated phenotype-dependent patterns (log-rank p < 0.01). Conclusion In refractory CS treated with Impella outcomes are strongly phenotype-dependent. Sepsis-associated CS represents an extreme-risk phenotype with poor short- and long-term survival, suggesting phenotype-guided patient selection and prospective validation of escalation strategies.
No takes yet. Share an insight, caveat, or question.
Chatzis et al. (2026) conducted a cohort in Refractory cardiogenic shock (n=409). Sepsis-associated cardiogenic shock phenotype under Impella 2.5/CP support vs. Other cardiogenic shock phenotypes (acute coronary syndrome, dilated cardiomyopathy/myocarditis, severe aortic stenosis, other causes) was evaluated on All-cause in-hospital and 12-month mortality (OR 4.65, 95% CI 2.03-12.07, p=0.0006). Sepsis-associated cardiogenic shock under Impella support independently predicted higher in-hospital mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: